December 8, 2025Hearts0 citationsOpen Access

A Review of Systemic Hypertension in the Cardiac Transplant Population: Pathophysiology, Management, and Future Directions

EREman RashedNewark Beth Israel Medical Center SSSwethika SundaravelAtrium Health Wake Forest Baptist JOJuan Ortega–LegaspiHospital of the University of Pennsylvania

Key Points

Hypertension affects 50-80% of cardiac transplant patients, leading to impaired graft survival and increased complications.
The review identifies key risk factors and causes of hypertension specific to heart transplant recipients.
Management strategies include addressing calcineurin inhibitors like cyclosporine, which are linked to hypertension post-transplant.
Understanding hypertension's impact on graft survival highlights critical treatment considerations for heart transplant recipients.

Abstract

Heart transplantation is the gold standard in patients with end stage heart failure, offering vastly improved survival, mortality and quality of life. However, hypertension occurring after cardiac transplantation is a serious issue, with the incidence ranging from 50 to 80% of patients. The pathophysiology of the hypertension encompasses a more varied and unique set of causes than those identified in non-organ transplant patients, particularly related to the use of calcineurin inhibitors (CNIs) especially cyclosporine. An in-depth understanding of hypertension after heart transplantation remains a critical issue that necessitates further clarification, due to its deleterious long-term consequence such as impaired graft survival, cardiac allograft vasculopathy (CAV), and overall survival. This article provides a comprehensive review of the prevalence, risk factors, etiology, complications, and management of hypertension after heart transplantation.

Ask AI

Helpful

Bookmark

View Full Paper